Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive
Article first published online: 28 JUN 2008
© 2008 The Authors. Journal compilation © 2008 Japanese Society of Psychiatry and Neurology
Psychiatry and Clinical Neurosciences
Volume 62, Issue 3, page 365, June 2008
How to Cite
Kawamura, S., Sakai, A., Endo, T. and Maruta, M. (2008), Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive. Psychiatry and Clinical Neurosciences, 62: 365. doi: 10.1111/j.1440-1819.2008.01808.x
- Issue published online: 28 JUN 2008
- Article first published online: 28 JUN 2008
- Received 30 July 2007; revised 22 December 2007; accepted 4 January 2008.
DEPRESSION AND HEADACHES are frequently associated comorbid disorders. In previous reports, psychiatrists have tended to regard headaches as an accompanying symptom of depression, while neurologists have tended to have the opposite opinion. The following case report characterizes migraine as a prime cause of major depression.
A 27-year-old woman presented because of a self-poisoning attempt with 12 mg of alprazolam. She had been suffering from major depression and sporadic headaches from the age of 24. After onset of the symptoms, she had often injured herself by cutting her arm and attempted to suicide by self-poisoning. A variety of antidepressants had failed to improve her symptoms, and she had been diagnosed as having borderline personality disorder comorbid with major depression.
A medical interview at her first visit revealed that her major depressive episode had been predominantly characterized by atypical features in DSM-IV such as overeating, hypersomnia, leaden paralysis, interpersonal rejection sensitivity, and mood reactivity. She had also suffered persistent aura and premonitory symptoms of migraine such as scintillating scotomas, photopsia, and phonophobia.1 Lomerizine, a calcium channel antagonist, was first administered at 10 mg/day for treatment of the migraine in combination with valproic acid at 600 mg/day. This medication led to prompt resolution of her self-injury and suicidal behaviors, but depressive mood with a series of migraine attacks paralleling each menstrual period persisted. Therefore, additionally, the patient was prescribed Ortho-Novum®7/7/7, an oral contraceptive containing ethinyl estradiol and norethindrone, to prevent ovulation. With this medication, all the symptoms immediately disappeared. Lomerizine and valproic acid were gradually withdrawn, and no recurrence has been noted for over 1 year.
Depression is one of the common premonitory symptoms of migraine, and a first-line treatment strategy for migraine showed some degree of clinical effectiveness on the depressive episode in the present case.1,2 Accordingly, it was considered that the patient's major depression was also a premonitory symptom of migraine. Ovarian hormones can alter neurotransmitter system theorized to play an important role in the pathogenesis of migraine.3 Although hormonal treatment of migraine is not a first-line strategy, due to an increased risk of ischemic stroke, oral contraceptives can have a broad effect on the character and frequency of migraine.4,5 We suggest that clinicians should check for the complication of migraine in depressive patients. Depressive patients with migraine might show a preferential response to management of migraine rather than medication with common antidepressants. In female patients, it is also prudent to be aware of any symptomatic relevance to the menstrual cycle, and that oral contraceptives have the potential to treat such problems.
- 5Sex hormones and headache. Rev. Neurol. 2000; 156 (Suppl. 4): S30–S41..